The long-term outcome of patients with IgA nephropathy treated with fish oil in a controlled trial. Mayo Nephrology Collaborative Group
Donadio JV, Grande JP, Bergstralh EJ, Dart RA, Larson TS, Spencer DC
Journal of the American Society of Nephrology : JASN · 100 citas
Etiquetas de revisión
Financiación no declaradaDatos neutrales que nuestra revisión registró sobre cómo se hizo este estudio. Describen el método, nunca si nos gusta el resultado.
Cómo se estudió
- Diseño
- Ensayo controlado aleatorizado (indexado por PubMed)
- Estudiado en
- Personas
- Resultado principal
- Eventos clínicos como enfermedad o muerte
Quién lo pagó
- Financiación
- Financiación no declarada
Publicación
- Publicado
- 1999-08-01 · J Am Soc Nephrol · vol. 10 · número 8 · págs. 1772–1777
- Editorial
- American Society of Nephrology
- Citado
- 209 citas · más que el 98% de estudios similares · 9.3× el promedio de su campo
- Impacto
- Entre el 10 % más citado de su campo
- Referencias
- 20 trabajos
- Acceso
- De pago
- Áreas de investigación
- Renal Diseases and Glomerulopathies · Chronic Kidney Disease and Diabetes · Fatty Acid Research and Health
- Palabras clave
- IgA nephropathy, fish oil supplementation, omega-3 fatty acids, kidney disease progression, end-stage renal disease, serum creatinine, proteinuria, blood pressure control, ACE inhibitors, long-term follow-up
- MeSH
- kidney, humans, kidney failure, chronic, glomerulonephritis, iga, proteinuria, hypertension, disease progression, creatinine, fish oils, enalapril, angiotensin-converting enzyme inhibitors, treatment outcome, cohort studies, longitudinal studies, double-blind method, female, male
6 autores
- James V. Donadío🇺🇸 · autor de correspondenciaMayo Clinic
- Joseph Peter Grande · autor de correspondencia
- Erik J. Bergstralh🇺🇸Mayo Clinic
- Richard A. Dart🇺🇸Marshfield Clinic; Marshfield Clinic; Marshfield Clinic
- Timothy S. Larson · autor de correspondencia
- Dorothy C. Spencer🇺🇸 · autor de correspondenciaMayo Clinic
Resumen
El texto original del estudio, en el idioma en que se publicó.
It was reported previously that dietary fish oil supplementation retarded the progression of renal disease in patients with IgA nephropathy in a multicenter, placebo-controlled, randomized, 2-yr clinical trial. The aim of this study was to determine the long-term influence of fish oil treatment on renal progression in observations on the study cohort of 106 patients extending beyond the 2-yr trial. Renal function was assessed by serial serum creatinine and 24-h urine protein measurements. Vital, end-stage renal disease (ESRD), and BP status and treatment beyond completion of the 2-yr trial were determined. As in the trial, the primary end point was an increase of 50% or more in the serum creatinine, and the secondary end point was ESRD. After a mean follow-up of 6.4 yr, 46 patients-17 in the fish oil group versus 29 in the placebo group-reached the primary end point (P = 0.002), and 27 patients-eight in the fish oil group versus 19 in the placebo group-developed ESRD (P = 0.009). At the end of the 2-yr trial, 75 patients (45 fish oil, 30 placebo) remained at risk for the primary end point. This is also when the double-blind part of the trial ended, allowing physicians to stop supplements, switch original placebo-assigned patients to fish oil, and continue fish oil in original fish oil-assigned patients. A significantly greater number of nonsupplemented placebo patients developed the primary end point (P = 0.02) and ESRD (P = 0.003) compared with long-term supplemented fish oil patients. Conversely, more fish oil-supplemented patients had stable renal function than nonsupplemented patients (P = 0.02). By intention, BP control, primarily treated with angiotensin-converting enzyme inhibition, was equal in the fish oil and placebo groups. Proteinuria was modestly reduced in both groups. It is concluded that early and prolonged treatment with fish oil slows renal progression for high-risk patients with IgA nephropathy.
Resumen vía Europe PMC. Los derechos de autor siguen siendo de los autores o la editorial.
Confianza de la comunidad
Cargando…
¿Cuánto confías en los hallazgos de este estudio?
Comentarios
¿Algo está mal aquí?
Señala este estudio si su información, etiquetas o financiación parecen incorrectas. Un editor revisa cada señalamiento.
Información educativa sobre investigación publicada. No es consejo médico ni una recomendación para empezar o dejar nada.